N. Auphan, J. DiDonato, C. Rosette, A. Helmberg, M. Karin (1995)
Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB SynthesisScience, 270
M. Kanai, K. Hanashiro, Song-Hee Kim, S. Hanai, A. Boulares, M. Miwa, K. Fukasawa (2007)
Inhibition of Crm1–p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ationNature Cell Biology, 9
W. Matsui, Qiuju Wang, J. Barber, Sarah Brennan, B. Smith, I. Borrello, I. Mcniece, Lan Lin, R. Ambinder, C. Peacock, D. Watkins, C. Huff, Richard Jones (2008)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.Cancer research, 68 1
Palumbo (2011)
Multiple myelomaN Engl J Med, 364
B. Culjkovic-Kraljacic, Aurélie Baguet, L. Volpon, A. Amri, K. Borden (2012)
The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation.Cell reports, 2 2
Zachary Hing, H. Fung, Parvathi Ranganathan, Shaneice Mitchell, D. El-Gamal, J. Woyach, K. Williams, V. Goettl, Jordan Smith, Xueyan Yu, Xiao-yan Meng, Qingxiang Sun, T. Cagatay, A. Lehman, D. Lucas, E. Baloglu, S. Shacham, M. Kauffman, J. Byrd, Y. Chook, R. Garzon, R. Lapalombella (2015)
Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignanciesLeukemia, 30
M. Asada, Takayuki Yamada, H. Ichijo, D. Delia, K. Miyazono, K. Fukumuro, Shuki Mizutani (1999)
Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiationThe EMBO Journal, 18
W. Senapedis, E. Baloglu, Y. Landesman (2014)
Clinical translation of nuclear export inhibitors in cancer.Seminars in cancer biology, 27
A. Noske, W. Weichert, S. Niesporek, A. Röske, A. Buckendahl, Ines Koch, J. Sehouli, M. Dietel, C. Denkert (2008)
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancerCancer, 112
R. Cornell, A. Rossi, R. Baz, C. Hofmeister, C. Shustik, J. Richter, Christine Chen, D. Vogl, E. Baloglu, W. Senapedis, J. Ellis, T. Williams, S. Shacham, M. Kauffman (2017)
Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple MyelomaBlood, 130
John Jeffers, E. Parganas, Youngsoo Lee, Chunying Yang, Jinling Wang, Jennifer Brennan, K. Maclean, Jiawen Han, T. Chittenden, J. Ihle, P. Mckinnon, J. Cleveland, G. Zambetti (2003)
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.Cancer cell, 4 4
M. Carroll, K. Borden (2013)
The oncogene eIF4E: using biochemical insights to target cancer.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 33 5
C. Argueta, T. Kashyap, B. Klebanov, Hua Chang, S. Friedlander, E. Baloglu, Y. Landesman, Margaret Lee, H. Gardner, S. Shacham, W. Senapedis (2017)
Abstract 329: Selinexor or KPT-8602 mediated XPO1 inhibition synergizes with dexamethasone to repress convergent pathways in the mTORC1 signaling network and drive cell death in multiple myelomaCancer Research, 77
J. Turner, Jana Dawson, M. Emmons, C. Cubitt, M. Kauffman, S. Shacham, L. Hazlehurst, D. Sullivan (2013)
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex VivoJournal of Cancer, 4
R. Cornell, A. Kassim (2016)
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityBone Marrow Transplantation, 51
Jakob Lovén, Heather Hoke, Charles Lin, Ashley Lau, David Orlando, C. Vakoc, J. Bradner, Tong Lee, R. Young (2013)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-EnhancersCell, 153
T. Muranen, M. Grönholm, G. Renkema, O. Carpén (2005)
Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlinOncogene, 24
J. Turner, D. Marchion, Jana Dawson, M. Emmons, L. Hazlehurst, P. Washausen, D. Sullivan (2009)
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.Cancer research, 69 17
Yang Yao, Yang Dong, F. Lin, Hui Zhao, Zan Shen, Ping Chen, Yuan‐jue Sun, Lina Tang, Shuier Zheng (2009)
The expression of CRM1 is associated with prognosis in human osteosarcoma.Oncology reports, 21 1
A. Jakubowiak, J. Jasielec, C. Rosenbaum, C. Cole, A. Chari, Jennifer Nam, E. Severson, L. Stephens, Kathryn Mcdonnell, Shaun Rosebeck, T. Zimmerman, T. Karrison, J. Zonder (2016)
Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)Blood, 128
R. Lapalombella, Qingxiang Sun, K. Williams, Larissa Tangeman, S. Jha, Y. Zhong, V. Goettl, Emilia Mahoney, C. Berglund, Sneha Gupta, Alicia Farmer, R. Mani, A. Johnson, D. Lucas, X. Mo, D. Daelemans, V. Sandanayaka, S. Shechter, D. McCauley, S. Shacham, M. Kauffman, Y. Chook, J. Byrd (2012)
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.Blood, 120 23
K. Sakakibara, Naoya Saito, Takuji Sato, A. Suzuki, Y. Hasegawa, J. Friedman, D. Kufe, D. Vonhoff, Tadahiko Iwami, T. Kawabe (2011)
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.Blood, 118 14
N. Bahlis, R. Kotb, M. Sebag, H. Sutherland, R. LeBlanc, D. White, C. Venner, T. Kouroukis, D. Bergstrom, A. McCurdy, M. Lalancette, W. Bensinger, S. Lentzsch, A. Col, M. Kauffman, S. Shacham, Jacqueline Jeha, Carla Picklesimer, J. Saint-Martin, C. Choe-Juliak, Christine Chen (2016)
Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp TrialBlood, 128
A. Azmi, A. Aboukameel, B. Bao, F. Sarkar, P. Philip, M. Kauffman, S. Shacham, R. Mohammad (2013)
Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice.Gastroenterology, 144 2
Simone Bonazzi, O. Eidam, Stephan Güttinger, J. Wach, I. Zemp, U. Kutay, K. Gademann (2010)
Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport.Journal of the American Chemical Society, 132 4
A. Razak, M. Mau-Soerensen, N. Gabrail, J. Gerecitano, A. Shields, T. Unger, J. Saint-Martin, R. Carlson, Y. Landesman, D. McCauley, T. Rashal, U. Lassen, R. Kim, Lee-Anne Stayner, M. Mirza, M. Kauffman, S. Shacham, A. Mahipal (2016)
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 34
T. Kashyap, C. Argueta, A. Aboukameel, T. Unger, B. Klebanov, R. Mohammad, I. Muqbil, A. Azmi, C. Drolen, W. Senapedis, Margaret Lee, M. Kauffman, S. Shacham, Y. Landesman (2016)
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell deathOncotarget, 7
J. Turner, D. Sullivan (2008)
CRM1-mediated nuclear export of proteins and drug resistance in cancer.Current medicinal chemistry, 15 26
P. Vogt, Hao Jiang, M. Aoki (2005)
Triple Layer Control: Phosphorylation, Acetylation and Ubiquitination of FOXO ProteinsCell Cycle, 4
R. Rosin-Arbesfeld, A. Cliffe, T. Brabletz, M. Bienz (2003)
Nuclear export of the APC tumour suppressor controls β‐catenin function in transcriptionThe EMBO Journal, 22
Tomomi Inoue, Jeremy Stuart, Richard Leno, C. Maki (2002)
Nuclear Import and Export Signals in Control of the p53-related Protein p73*The Journal of Biological Chemistry, 277
J. Turner, Jana Dawson, S. Grant, K. Shain, W. Dalton, Yun Dai, M. Meads, R. Baz, M. Kauffman, S. Shacham, D. Sullivan (2016)
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsJournal of Hematology & Oncology, 9
Yong-sheng Tu, Xiao-Long Kang, Jia-Guo Zhou, Xiao-fei Lv, Yongbo Tang, Y. Guan (2011)
Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells.European journal of pharmacology, 670 2-3
J. Etchin, Qi Sun, A. Kentsis, Alicia Farmer, Zi Zhang, Takaomi Sanda, Marc Mansour, C. Barceló, D. McCauley, M. Kauffman, S. Shacham, A. Christie, Andrew Kung, S. Rodig, Y. Chook, A. Look (2012)
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsLeukemia, 27
Christine Chen, M. Gutierrez, D. Siegel, J. Richter, N. Wagner-Johnston, C. Hofmeister, J. Berdeja, N. Gabrail, R. Baz, M. Mau-Sørensen, S. Trudel, R. Tiedemann, V. Kukreti, N. Areethamsirikul, A. Azmi, T. Kashyap, Y. Landesman, T. Marshall, J. Mccartney, J. Saint-Martin, Sasha Norori, M. Savona, T. Rashal, R. Carlson, M. Mirza, S. Shacham, M. Kauffman, D. Reece (2014)
Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)Blood, 124
T. Maekawa, Y. Osawa, T. Izumi, Shigeki Nagao, K. Takano, Yoshikiyo Okada, N. Tachi, M. Teramoto, T. Kawamura, T. Horiuchi, R. Saga, S. Kato, T. Yamamura, J. Watanabe, A. Kobayashi, Shinichi Kobayashi, Kimiya Sato, M. Hashimoto, S. Suzu, F. Kimura (2017)
Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosisLeukemia, 31
S. Seidl, H. Kaufmann, J. Drach (2003)
New insights into the pathophysiology of multiple myeloma.The Lancet. Oncology, 4 9
A. Shen, Yuchan Wang, Yue-ming Zhao, Lin Zou, Lin-lin Sun, Chun Cheng (2009)
EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSISNeurosurgery, 65
I. Arregi, Jorge Falces, Anne Olazabal-Herrero, Marián Alonso-Mariño, S. Taneva, J. Rodriguez, M. Urbaneja, S. Bañuelos (2015)
Leukemia-Associated Mutations in Nucleophosmin Alter Recognition by CRM1: Molecular Basis of Aberrant TransportPLoS ONE, 10
J. Kuruvilla, M. Savona, R. Baz, P. Mau-Sorensen, N. Gabrail, R. Garzon, R. Stone, Michael Wang, L. Savoie, P. Martin, I. Flinn, Meagan Jacoby, T. Unger, J. Saint-Martin, T. Rashal, S. Friedlander, R. Carlson, M. Kauffman, S. Shacham, M. Gutierrez (2017)
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.Blood, 129 24
R. Fragomeni, H. Chung, Y. Landesman, W. Senapedis, J. Saint-Martin, H. Tsao, K. Flaherty, S. Shacham, M. Kauffman, J. Cusack (2013)
CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant MelanomaMolecular Cancer Therapeutics, 12
Christine Chen, D. Siegel, M. Gutierrez, Meagan Jacoby, C. Hofmeister, N. Gabrail, R. Baz, M. Mau-Sørensen, J. Berdeja, M. Savona, L. Savoie, S. Trudel, N. Areethamsirikul, T. Unger, T. Rashal, T. Hanke, M. Kauffman, S. Shacham, D. Reece (2018)
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.Blood, 131 8
M. Pourdehnad, Morgan Truitt, Imran Siddiqi, Gregory Ducker, K. Shokat, D. Ruggero (2013)
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancersProceedings of the National Academy of Sciences, 110
Xiaohong Han, Jianfei Wang, Yinchen Shen, Ningning Zhang, Shuai Wang, Jiarui Yao, Yuankai Shi (2015)
CRM1 as a new therapeutic target for non-Hodgkin lymphoma.Leukemia research, 39 1
R. Tiedemann, Y. Zhu, Jessica Schmidt, C. Shi, C. Sereduk, H. Yin, S. Mousses, A. Stewart (2012)
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.Cancer research, 72 3
Tony Huang, N. Kudo, Minoru Yoshida, S. Miyamoto (2000)
A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexesProceedings of the National Academy of Sciences of the United States of America, 97
Arundhati Das, G. Wei, K. Parikh, Delong Liu (2015)
Selective inhibitors of nuclear export (SINE) in hematological malignanciesExperimental Hematology & Oncology, 4
Yan Cui, J. Turner, Jana Dawson, Juan Gomez, K. Shain, M. Meads, E. Baloglu, W. Dalton, T. Nishihori, D. Sullivan (2016)
The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple MyelomaBlood, 128
Darui Xu, N. Grishin, Y. Chook (2012)
NESdb: a database of NES-containing CRM1 cargoesMolecular Biology of the Cell, 23
J. Turner, Jana Dawson, S. Grant, K. Shain, Yun Dai, C. Cubitt, R. Baz, T. Nishihori, M. Kauffman, S. Shacham, D. Sullivan (2014)
Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple MyelomaBlood, 124
M. Seyed, I. Jantan, S. Bukhari (2014)
Emerging Anticancer Potentials of Goniothalamin and Its Molecular MechanismsBioMed Research International, 2014
K. Parikh, S. Cang, Arunabh Sekhri, Delong Liu (2014)
Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agentsJournal of Hematology & Oncology, 7
M. Chesi, G. Matthews, G. Matthews, Victoria Garbitt, Stephen Palmer, J. Shortt, J. Shortt, M. Lefebure, M. Lefebure, A. Stewart, R. Johnstone, R. Johnstone, P. Bergsagel (2012)
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.Blood, 120 2
S. Mutka, W. Yang, S. Dong, Shannon Ward, Darren Craig, P. Timmermans, S. Murli (2009)
Identification of nuclear export inhibitors with potent anticancer activity in vivo.Cancer research, 69 2
E. Susaki, K. Nakayama (2007)
Multiple Mechanisms for p27Kip1 Translocation and DegradationCell Cycle, 6
N. Kudo, N. Matsumori, Hiroshi Taoka, Daisuke Fujiwara, E. Schreiner, B. Wolff, Minoru Yoshida, S. Horinouchi (1999)
Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region.Proceedings of the National Academy of Sciences of the United States of America, 96 16
Christine Chen, R. Kotb, M. Sebag, R. LeBlanc, H. Sutherland, D. White, C. Venner, T. Kouroukis, D. Bergstrom, A. McCurdy, M. Lalancette, W. Bensinger, S. Lentzsch, A. Col, M. Kauffman, S. Shacham, Jacqueline Jeha, Carla Picklesimer, J. Saint-Martin, C. Choe-Juliak, N. Bahlis (2016)
Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple MyelomaBlood, 128
K. Kojima, S. Kornblau, V. Ruvolo, A. Dilip, S. Duvvuri, R. Davis, Min Zhang, Zhiqiang Wang, K. Coombes, Nianxiang Zhang, Y. Qiu, J. Burks, H. Kantarjian, S. Shacham, M. Kauffman, M. Andreeff (2012)
Prognostic impact and targeting of CRM1 in acute myeloid leukemia.Blood, 121 20
Y. Takenaka, T. Fukumori, T. Yoshii, N. Oka, H. Inohara, H. Kim, R. Bresalier, A. Raz (2004)
Nuclear Export of Phosphorylated Galectin-3 Regulates Its Antiapoptotic Activity in Response to Chemotherapeutic DrugsMolecular and Cellular Biology, 24
R. Garzon, M. Savona, R. Baz, M. Andreeff, N. Gabrail, M. Gutierrez, L. Savoie, P. Mau-Sorensen, N. Wagner-Johnston, K. Yee, T. Unger, J. Saint-Martin, R. Carlson, T. Rashal, T. Kashyap, B. Klebanov, S. Shacham, M. Kauffman, R. Stone (2017)
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.Blood, 129 24
Y. Tai, Y. Landesman, C. Acharya, Y. Calle, M. Zhong, M. Cea, Daniel Tannenbaum, A. Cagnetta, M. Reagan, Aditya Munshi, W. Senapedis, J. Saint-Martin, T. Kashyap, S. Shacham, M. Kauffman, Yu-mei Gu, Lizi Wu, I. Ghobrial, F. Zhan, A. Kung, S. Schey, P. Richardson, Nikhil Munshi, K. Anderson (2014)
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsLeukemia, 28
T. Kashyap, B. Klebanov, Margaret Lee, Y. Landesman (2015)
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Synergistic Anti-Tumor Activity in Combination with Dexamethasone Characterized By Specific Pattern of Gene Expression in Multiple Myeloma (MM)Blood, 126
C. Argueta, Hua Chang, T. Kashyap, Sivan Elloul, S. Friedlander, Margaret Lee, M. Kauffman, S. Shacham, W. Senapedis, E. Baloglu (2016)
Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple MyelomaBlood, 128
R. Hill, B. Cautain, N. Pedro, W. Link (2013)
Targeting nucleocytoplasmic transport in cancer therapyOncotarget, 5
W. Jiao, J. Datta, Huei-min Lin, M. Dundr, S. Rane (2006)
Nucleocytoplasmic Shuttling of the Retinoblastoma Tumor Suppressor Protein via Cdk Phosphorylation-dependent Nuclear Export*Journal of Biological Chemistry, 281
J. Turner, Jana Dawson, D. Sullivan (2012)
Nuclear export of proteins and drug resistance in cancer.Biochemical pharmacology, 83 8
Shaun Rosebeck, Mattina Alonge, Malathi Kandarpa, A. Mayampurath, S. Volchenboum, J. Jasielec, D. Dytfeld, Sean Maxwell, Stephanie Kraftson, D. McCauley, S. Shacham, M. Kauffman, A. Jakubowiak (2015)
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and SelinexorMolecular Cancer Therapeutics, 15
Zheng-lan Huang, M. Gao, Qian-yin Li, Kun Tao, Q. Xiao, Wei-xi Cao, W. Feng (2013)
Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleusOncotarget, 4
J. Turner, Jana Dawson, C. Cubitt, Erkan Baluglo, S. Grant, Yun Dai, K. Shain, W. Dalton, S. Shacham, W. Senapedis, D. Sullivan (2015)
Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple MyelomaBlood, 126
Haibo Sun, N. Hattori, W. Chien, Qiao-Yang Sun, M. Sudo, E. G., L. Ding, Su-Lin Lim, S. Shacham, M. Kauffman, T. Nakamaki, H. Koeffler (2014)
KPT-330 has antitumour activity against non-small cell lung cancerBritish Journal of Cancer, 111
Kejie Zhang, Michael Wang, Archito Tamayo, S. Shacham, M. Kauffman, John Lee, L. Zhang, Zhishuo Ou, Changping Li, Luhong Sun, R. Ford, L. Pham (2013)
Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.Experimental hematology, 41 1
Thomas Alexander, N. Lacayo, J. Choi, R. Ribeiro, C. Pui, J. Rubnitz (2016)
Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 34
D. Vogl, D. Dingli, R. Cornell, C. Huff, S. Jagannath, D. Bhutani, J. Zonder, R. Baz, Ajay Nooka, A. Nooka, J. Richter, C. Cole, R. Vij, A. Jakubowiak, R. Abonour, G. Schiller, Terri Parker, L. Costa, David Kaminetzky, J. Hoffman, A. Yee, A. Chari, D. Siegel, R. Fonseca, S. Wier, G. Ahmann, Ilse Lopez, M. Kauffman, S. Shacham, J. Saint-Martin, Carla Picklesimer, C. Choe-Juliak, A. Stewart (2018)
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 9
D. Vogl, D. Dingli, R. Cornell, C. Huff, S. Jagannath, D. Bhutani, R. Baz, A. Nooka, J. Richter, C. Cole, R. Vij, A. Jakubowiak, R. Abonour, G. Schiller, Terri Parker, L. Costa, David Kaminetzky, J. Hoffman, A. Yee, A. Chari, D. Siegel, R. Fonseca, S. Vanwier, G. Ahmann, Ilse Lopez, M. Kauffman, S. Shacham, J. Saint-Martin, Carla Picklesimer, S. Friedlander, C. Choe-Juliak, A. Stewart (2016)
Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM StudyBlood, 128
K. Machlus, Stephen Wu, Prakrith Vijey, T. Soussou, Zhi-Jian Liu, Zhi-Jian Liu, E. Shacham, T. Unger, T. Kashyap, B. Klebanov, Martha Sola-Visner, Martha Sola-Visner, M. Crochiere, J. Italiano, J. Italiano, Y. Landesman (2017)
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.Blood, 130 9
W. Ghanima, J. Geyer, Christina Lee, L. Boiocchi, Allison Imahiyerobo, A. Orazi, J. Bussel (2014)
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-upHaematologica, 99
M. Maekawa, Takuya Yamamoto, E. Nishida (2004)
Regulation of subcellular localization of the antiproliferative protein Tob by its nuclear export signal and bipartite nuclear localization signal sequences.Experimental cell research, 295 1
J. Etchin, T. Sanda, M. Mansour, A. Kentsis, J. Montero, B. Le, A. Christie, D. McCauley, S. Rodig, M. Kauffman, S. Shacham, R. Stone, A. Letai, A. Kung, A. Look (2013)
KPT‐330 inhibitor of CRM1 (XPO1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of T‐cell acute lymphoblastic leukaemia and acute myeloid leukaemiaBritish Journal of Haematology, 161
Szu-Chin Fu, Hsuan-Cheng Huang, P. Horton, Hsueh‐Fen Juan (2012)
ValidNESs: a database of validated leucine-rich nuclear export signalsNucleic Acids Research, 41
R. Baz, K. Shain, M. Alsina, J. Brayer, T. Rashal, J. Cooksey, J. Turner, Jana Dawson, D. Sullivan (2016)
Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).Journal of Clinical Oncology, 34
O. Kalid, D. Warshaviak, S. Shechter, W. Sherman, S. Shacham (2012)
Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitorsJournal of Computer-Aided Molecular Design, 26
Parvathi Ranganathan, Xueyan Yu, Caroline Na, R. Santhanam, S. Shacham, M. Kauffman, A. Walker, R. Klisovic, W. Blum, M. Caligiuri, C. Croce, G. Marcucci, R. Garzon (2012)
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.Blood, 120 9
Kirsty Brodie, B. Henderson (2012)
Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the CentrosomeThe Journal of Biological Chemistry, 287
W. Chng, Gaofeng Huang, Tae-Hoon Chung, S. Ng, Natalia Gonzalez-Paz, T. Troska-Price, G. Mulligan, M. Chesi, P. Bergsagel, R. Fonseca (2011)
Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myelomaLeukemia, 25
L. Golomb, D. Bublik, S. Wilder, R. Nevo, Vladimír Kišš, Kristina Grabušić, S. Volarevic, M. Oren (2012)
Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis.Molecular cell, 45 2
Wei-yi Huang, L. Yue, W. Qiu, Li-wei Wang, Xiaodong Zhou, Yuan-jue Sun (2009)
Prognostic value of CRM1 in pancreas cancer.Clinical and investigative medicine. Medecine clinique et experimentale, 32 6
J. Etchin, J. Etchin, A. Berezovskaya, Amy Conway, I. Galinsky, Richard Stone, E. Baloglu, W. Senapedis, Y. Landesman, M. Kauffman, S. Shacham, Jean Wang, Jean Wang, A. Look, A. Look (2016)
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cellsLeukemia, 31
T. Meissner, E. Krause, U. Vinkemeier (2004)
Ratjadone and leptomycin B block CRM1‐dependent nuclear export by identical mechanismsFEBS Letters, 576
Jessica Schmidt, E. Braggio, K. Kortuem, J. Egan, Y. Zhu, C. Xin, R. Tiedemann, Stephen Palmer, Victoria Garbitt, D. McCauley, M. Kauffman, S. Shacham, M. Chesi, P. Bergsagel, A. Stewart (2013)
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276Leukemia, 27
H. Inoue, M. Kauffman, S. Shacham, Y. Landesman, Joy Yang, C. Evans, R. Weiss (2013)
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.The Journal of urology, 189 6
A. Oloumi, S. MacPhail, Peter Johnston, J. Banáth, Peggy Olive (2000)
Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.Cancer research, 60 20
E. Newlands, G. Rustin, M. Brampton (1996)
Phase I trial of elactocin.British Journal of Cancer, 74
S. Gaubatz, J. Lees, G. Lindeman, D. Livingston (2001)
E2F4 Is Exported from the Nucleus in a CRM1-Dependent MannerMolecular and Cellular Biology, 21
Yan Cheng, M. Holloway, K. Nguyen, D. McCauley, Y. Landesman, M. Kauffman, S. Shacham, R. Altura (2014)
XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast CancerMolecular Cancer Therapeutics, 13
G. Gravina, W. Senapedis, D. McCauley, E. Baloglu, S. Shacham, C. Festuccia (2014)
Nucleo-cytoplasmic transport as a therapeutic target of cancerJournal of Hematology & Oncology, 7
D. Kuter (2007)
New thrombopoietic growth factors.Blood, 109 11
M. Gounder, A. Zer, W. Tap, S. Salah, M. Dickson, Abha Gupta, M. Keohan, H. Loong, S. D’Angelo, S. Baker, M. Condy, Kjirsten Nyquist-Schultz, L. Tanner, J. Erinjeri, Francis Jasmine, S. Friedlander, R. Carlson, T. Unger, J. Saint-Martin, T. Rashal, J. Ellis, M. Kauffman, S. Shacham, G. Schwartz, A. Razak (2016)
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 26
Clinical Lymphoma Myeloma & Leukemia – Unpaywall
Published: Mar 18, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.